OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Core Insights - OKYO Pharma Limited announced a 68% improvement in responder rates for patients achieving both conjunctival staining and ocular pain endpoints in their Phase 2 Dry Eye Disease trial [1][3] - The company is focused on developing innovative ocular therapies for inflammatory dry eye disease and neuropathic corneal pain, addressing a significant unmet need in the market [1][12] Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company listed on NASDAQ, dedicated to developing therapies for dry eye disease and neuropathic corneal pain [12] - The company is advancing its program to provide treatment alternatives for patients suffering from ocular pain associated with dry eye disease [2][12] Clinical Trial Results - The Phase 2 trial of OK-101 demonstrated that 34.2% of patients in the treatment group showed a reduction in both conjunctival staining and pain symptoms, compared to 20.3% in the placebo group [3] - A similar trend was observed for patients reporting a reduction in conjunctival staining and burning/stinging symptoms, with 32.9% in the treatment group versus 20.3% in the placebo group, indicating a 62% improvement [3] - The trial established conjunctival staining and ocular pain as potential co-primary endpoints for future studies, which are crucial for regulatory approval [8][10] Future Directions - The company plans to evaluate next steps for dry eye treatment in collaboration with advisors and regulatory agencies [2] - OK-101 is designed to enhance residence time in the ocular environment, potentially offering a long-acting solution for dry eye disease [11]